Join Sagimet Biosciences for a virtual event featuring key opinion leader (KOL) Julie Harper, MD, Founding Director and past President of the American Acne and Rosacea Society. Dr. Harper will join Company management for a review of the 52-week data from license partner Ascletis’ open-label Phase 3 clinical trial of denifanstat in moderate to severe acne vulgaris in China (OLE), and an update on the Company’s planned AURORA Phase 3 clinical trial of denifanstat for the treatment of moderate to severe acne in the U.S.

In the OLE, subjects treated with denifanstat showed improvements in all efficacy endpoints (secondary endpoints of the trial) beyond those observed at 12 weeks. Denifanstat was generally well tolerated throughout the trial. These results will be presented at the European Academy of Dermatology and Venereology Congress (EADV 2026), building on the topline results announced in February 2026.

Sagimet’s AURORA Phase 3 clinical trial of denifanstat in moderate to severe acne in the U.S. is expected to initiate in the fourth quarter of 2026. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor with potential as a novel mechanism of action to address moderate to severe acne, a condition that impacts more than 10 million people annually in the U.S.

A live question and answer session will follow the formal presentations.